College of Health and Human Sciences, Purdue University, West Lafayette, IN, United States.
School of Nursing, Yale University, West Haven, CT, United States.
Front Endocrinol (Lausanne). 2022 Aug 17;13:918095. doi: 10.3389/fendo.2022.918095. eCollection 2022.
The prevalence of diabetes and its impact on mortality after acute myocardial infarction (AMI) are well-established. Sex-specific analyses of the impact of diabetes on all-cause mortality after AMI have not been updated and comprehensively investigated.
To conduct a systematic review and meta-analysis that examined sex-specific short-term, mid-term and long-term all-cause mortality associated with diabetes among AMI survivors (diabetes versus non-diabetes patients in men and women separately), using up-to-date data.
We systematically searched Embase and MEDLINE for studies that were published from inception to November 14, 2021. Studies were included if (1) they studied post-AMI all-cause-mortality in patients with and without diabetes, (2) sex-specific all-cause mortality at short-term (in-hospital or within 90 days after discharge), mid-term (>90 days and within 5 years), and/or long-term (>5 years) were reported. From eligible studies, we used random effects meta-analyses models to estimate pooled unadjusted and adjusted sex-specific risk ratio (RR) of all-cause mortality at short-, mid-, and long-term follow-up for adults with diabetes compared with those without diabetes.
Of the 3647 unique studies identified, 20 studies met inclusion criteria. In the unadjusted analysis (Total N=673,985; women=34.2%; diabetes patients=19.6%), patients with diabetes were at a higher risk for all-cause mortality at short-term (men: RR, 2.06; women: RR, 1.83); and mid-term follow-up (men: RR, 1.69; women: RR, 1.52) compared with those without diabetes in both men and women. However, when adjusted RRs were used (Total N=7,144,921; women=40.0%; diabetes patients=28.4%), the associations between diabetes and all-cause mortality in both men and women were attenuated, but still significantly elevated for short-term (men: RR, 1.16; 95% CI, 1.12-1.20; women: RR, 1.29; 95% CI, 1.15-1.46), mid-term (men: RR, 1.39; 95% CI, 1.31-1.46; women: RR, 1.38; 95% CI, 1.20-1.58), and long-term mortality (men: RR, 1.58; 95% CI, 1.22-2.05; women: RR, 1.76; 95% CI, 1.25-2.47). In men, all-cause mortality risk associated with diabetes tended to increase with the duration of follow-up (p<0.0001).
Diabetes has substantial and sustained effects on post-AMI all-cause mortality at short-term, mid-term and long-term follow-up, regardless of sex. Tailoring AMI treatment based on patients' diabetes status, duration of follow-up and sex may help narrow the gap in all-cause mortality between patients with diabetes and those without diabetes.
糖尿病的患病率及其对急性心肌梗死(AMI)后死亡率的影响已得到充分证实。针对糖尿病对 AMI 幸存者全因死亡率影响的性别特异性分析尚未得到更新和全面调查。
利用最新数据,进行系统评价和荟萃分析,以检查 AMI 幸存者中(男性和女性的糖尿病患者与非糖尿病患者分别比较)短期、中期和长期与糖尿病相关的全因死亡率的性别特异性情况。
我们系统地检索了 Embase 和 MEDLINE,以查找截至 2021 年 11 月 14 日发表的研究。如果研究(1)研究了 AMI 后有和无糖尿病患者的全因死亡率,(2)报告了短期(住院或出院后 90 天内)、中期(>90 天且<5 年内)和/或长期(>5 年内)的性别特异性全因死亡率,则将其纳入研究。从合格研究中,我们使用随机效应荟萃分析模型来估计患有糖尿病的成年人与无糖尿病的成年人相比,短期、中期和长期随访的全因死亡率的未调整和调整后性别特异性风险比(RR)。
在 3647 项独特的研究中,有 20 项研究符合纳入标准。在未调整分析中(总 N=673985;女性=34.2%;糖尿病患者=19.6%),与无糖尿病患者相比,男性和女性的糖尿病患者短期(男性:RR,2.06;女性:RR,1.83)和中期(男性:RR,1.69;女性:RR,1.52)全因死亡率风险更高。然而,当使用调整后的 RR 时(总 N=7144921;女性=40.0%;糖尿病患者=28.4%),糖尿病与男性和女性全因死亡率之间的关联减弱,但仍显著升高,尤其是在短期(男性:RR,1.16;95%CI,1.12-1.20;女性:RR,1.29;95%CI,1.15-1.46)、中期(男性:RR,1.39;95%CI,1.31-1.46;女性:RR,1.38;95%CI,1.20-1.58)和长期死亡率(男性:RR,1.58;95%CI,1.22-2.05;女性:RR,1.76;95%CI,1.25-2.47)。在男性中,与糖尿病相关的全因死亡风险随着随访时间的延长而增加(p<0.0001)。
无论性别如何,糖尿病对 AMI 后短期、中期和长期全因死亡率都有实质性和持续的影响。根据患者的糖尿病状况、随访时间和性别调整 AMI 治疗,可能有助于缩小糖尿病患者和非糖尿病患者之间的全因死亡率差距。